Prognostic Factors of Primary Adenocarcinoma of the Uterine Cervix

Chen, Ruey-Jien; Chang, Daw-Yuan; Yen, Men‐Luh; Lee, Evelyn Fung; Huang, Su‐Cheng; Chow, Song‐Nan; Hsieh, Chang‐Yao

doi:10.1006/gyno.1998.4971

Cited by 58 publications

(36 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many previous reports indicate that EGF and TGF-· might be strongly associated with the enzymatic degradation of ECM components and the invasion process of cervical, endometrial and ovarian carcinomas [11-16, 27, 29]. However, the biological implication of these growth factors on the mechanism of invasion in cervical adenocarcinoma cells has not been elucidated, although they have aggressive clinical characteristics with rapid expansion of the lower uterine segment and early dissemination [2][3][4][5]. We previously examined the motility and the invasive activity of var- TCM samples were mixed with SDS sample buffer and then immediately applied, without heating or reducing, to gelatin-embedded SDS-polyacrylamide gels.…”

Section: Discussionmentioning

confidence: 99%

“…Cervical adenocarcinoma is generally of a more aggressive clinical nature than squamous cell carcinoma with a propensity for early invasion and dissemination. The treatment of cervical adenocarcinoma is difficult because of its tendency to remote spread, poor prognosis and resistance to radiation and systemic therapies [2][3][4][5]. Although the optimal management of this disease has been a challenge and a subject of debate, the regulatory mechanism of invasive activity of cervical adenocarcinoma cells has not been fully understood.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of EGF and TGF-α on Invasion and Proteinase Expression of Uterine Cervical Adenocarcinoma OMC-4 Cells

Ueda¹,

Fujii²,

Yoshizawa³

et al. 1998

Invasion Metastasis

View full text Add to dashboard Cite

Uterine cervical adenocarcinoma typically is an aggressive neoplasm with a propensity for early invasion and dissemination; however, the regulatory mechanism of invasive activity of cervical adenocarcinoma cells has not been fully understood. In this study, biological effects of epidermal growth factor (EGF) and transforming growth factor (TGF)-α on invasion and proteinase expression of human cervical adenocarcinoma OMC-4 cells were investigated. Tumor cell migration along a gradient of substratum-bound fibronectin and invasion into the reconstituted basement membrane were stimulated by 0.1–10 nM EGF and TGF-α in a concentration-dependent manner. Their effects on tumor cell migration were also confirmed by wound assay. The zymography of tumor-conditioned medium showed that the treatment of OMC-4 cells with EGF and TGF-α resulted in the increase of matrix metalloproteinase (MMP)-2 and urokinase-type plasminogen activator (uPA). Matrilysin (MMP-7), also secreted by OMC-4 cells, was not affected by these growth factors. These results suggest that EGF and TGF-α act as positive regulators on the invasion of cervical adenocarcinoma cells, which may be associated with their stimulatory effects on tumor cell motility and the induction of type IV collagenase and uPA secreted by tumor cells.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Effects of EGF and TGF-α on Invasion and Proteinase Expression of Uterine Cervical Adenocarcinoma OMC-4 Cells

Ueda¹,

Fujii²,

Yoshizawa³

et al. 1998

Invasion Metastasis

View full text Add to dashboard Cite

show abstract

“…International Federation of Gynaecology and Obstetrics (FIGO) stage, histological grade, tumour size, lymphovascular space invasion and lymph node metastasis are major prognostic factors reported in literature (1)(2)(3). Nevertheless, additional information guiding the patient's management would be helpful.…”

mentioning

confidence: 99%

Prognostic Significance of Pre-treatment Serum C-Reactive Protein Level in Patients with Adenocarcinoma of the Uterine Cervix

Bodner‐Adler

Kimberger

Schneidinger

et al. 2016

View full text Add to dashboard Cite

Cervical cancer is the third most common cancer in women worldwide, with peak incidence in the 40-to 45-year age group (1). Adenocarcinoma of the uterine cervix is a rare histological subtype, representing up to 20% of cervical carcinoma. International Federation of Gynaecology and Obstetrics (FIGO) stage, histological grade, tumour size, lymphovascular space invasion and lymph node metastasis are major prognostic factors reported in literature (1-3). Nevertheless, additional information guiding the patient's management would be helpful. There is much interest in prognostic factors to permit more accurate patient stratification, that will improve clinical decision-making and may contribute to more rational treatment options. Current guidelines for cervical cancer recommend the same treatment regardless of histological subtype, although lower survival rates were reported for the adenocarcinoma subtype (4). Therefore increasing efforts should focus on prognosticators in adenocarcinoma of the uterine cervix.C-Reactive protein (CRP) is widely used in clinical routine as the most important acute-phase serum protein for monitoring infection. CRP has also been shown to be elevated in patients with a variety of cancer types and an association with prognosis was found. Several studies have shown that patients with cancer have a higher level of circulating CRP than healthy controls prior to clinical diagnosis (5-8). In addition, an increase in serum CRP has been reported to be associated with poor prognosis in oesophageal, liver, colon and lung cancer (9-12). Elevated serum CRP levels have also been linked to impaired survival in patients with different gynaecological malignancies, including cervical, ovarian and endometrial cancer (13-15). However, only few studies reported on the prognostic role of CRP expression in cervical carcinoma (14, 16), with no data investigating exclusively the histological subtype adenocarcinoma of the uterine cervix.The aim of the present study was to evaluate whether the pre-treatment serum CRP level might be used as a prognostic parameter in patients with adenocarcinoma of the uterine cervix and to investigate a possible correlation between the serum CRP level and various clinicopathological parameters. 4691

show abstract

“…9,10 No information on the use of diethylstilboestrol (DES) was provided in those studies. DES use by the mother was not an etiologic factor in young females with clear cell carcinoma of the cervix or vagina according to an earlier study from Norway.…”

Section: Discussionmentioning

confidence: 99%

“…9,11,18,19,21,22,25,27,29,35,39 This may be due to the inclusion of histologic groups of patient with adenosquamous carcinoma 11,22,25 or clear cell carcinoma 11 in the other studies or to the use of different grading systems. 9,25,35 When comparing the prognosis for patients with glandular and nonglandular carcinomas of the uterine cervix, several authors have found inferior survival for patients with glandular tumors. 3,5,10,23,26,34,36,39,40 Because of these differences, speculations have been made on the relevance of a similar grading system for patients with glandular and nonglandular carcinomas of the uterine cervix.…”

Section: Discussionmentioning

confidence: 99%

Histologic subtype has minor importance for overall survival in patients with adenocarcinoma of the uterine cervix

Alfsen

Kristensen

Skovlund

et al. 2001

Cancer

View full text Add to dashboard Cite

Prognostic Factors of Primary Adenocarcinoma of the Uterine Cervix

Cited by 58 publications

References 30 publications

Effects of EGF and TGF-α on Invasion and Proteinase Expression of Uterine Cervical Adenocarcinoma OMC-4 Cells

Effects of EGF and TGF-α on Invasion and Proteinase Expression of Uterine Cervical Adenocarcinoma OMC-4 Cells

Prognostic Significance of Pre-treatment Serum C-Reactive Protein Level in Patients with Adenocarcinoma of the Uterine Cervix

Histologic subtype has minor importance for overall survival in patients with adenocarcinoma of the uterine cervix

Contact Info

Product

Resources

About